Alan M Laibelman

US Patent:

6667306, Dec 23, 2003

Filed:

Jan 7, 1999

Appl. No.:

09/226103

Inventors:

Alan M. Laibelman - San Mateo CA
Hans-Michael Jantzen - San Francisco CA
Pamela B. Conley - Palo Alto CA
Larry J. Fretto - Palo Alto CA
Robert M. Scarborough - Belmont CA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D51314

US Classification:

5142228, 544 9, 544 6

Abstract:

The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors: In formula (I), W is carbon or nitrogen, wherein at least one W is a carbon; and Y is nitrogen, oxygen, or sulfur. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.

US Patent:

57212147, Feb 24, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/485433

Inventors:

Charles K. Marlowe - Redwood City CA
Robert M. Scarborough - Belmont CA
Alan M. Laibelman - Menlo Park CA
Uma Sinha - San Francisco CA
Bing-Yan Zhu - Foster City CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 3800
C07K 3806
C07K 500
C07K 700

US Classification:

514 18

Abstract:

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

US Patent:

60461691, Apr 4, 2000

Filed:

Jun 7, 1995

Appl. No.:

8/486386

Inventors:

Charles K. Marlowe - Redwood City CA
Robert M. Scarborough - Belmont CA
Alan M. Laibelman - Menlo Park CA
Uma Sinha - San Francisco CA
Bing-Yan Zhu - Foster City CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 3800
A61K 3805
C07K 3906
C07K 700

US Classification:

514 18

Abstract:

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

US Patent:

62457438, Jun 12, 2001

Filed:

May 15, 1998

Appl. No.:

9/077001

Inventors:

Charles K. Marlowe - Belmont CA
Robert M. Scarborough - Belmont CA
Alan M. Laibelman - San Mateo CA
Uma Sinha - San Francisco CA
Bing-Yan Zhu - Belmont CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 3800
C07K 700
C07K 500

US Classification:

514 18

Abstract:

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

US Patent:

59197650, Jul 6, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/483470

Inventors:

Charles K. Marlowe - Redwood City CA
Robert M. Scarborough - Belmont CA
Alan M. Laibelman - Menlo Park CA
Uma Sinha - San Francisco CA
Bing-Yan Zhu - Foster City CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 3800
A61K 3805
C07K 3806
C07K 700

US Classification:

514 18

Abstract:

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

US Patent:

59169087, Jun 29, 1999

Filed:

Nov 9, 1995

Appl. No.:

8/556178

Inventors:

Neill A. Giese - San Francisco CA
Nathalie Lokker - San Francisco CA
Alan M. Laibelman - Menlo Park CA
Robert M. Scarborough - Belmont CA

Assignee:

COR Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 31415
C12N 999
C12N 912

US Classification:

514406

Abstract:

A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of the formula: ##STR1## wherein: R. sub. 1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, polyaromatic, polyaromatic carbonyl, polyheteroaromatic or polyheteroaromatic carbonyl; R. sub. 2 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, lower hydrocarboyl, 5- or 6-membered heterocyclic aromatic carbonyl, polyaromatic or polyheteroaromatic; R. sub. 3 is H or lower alkyl; R. sub. 5 is H, lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocyclic aromatic, halogen, or cyano; and R. sub. 6 is H or lower hydrocarboyl.

US Patent:

54280214, Jun 27, 1995

Filed:

Jan 27, 1994

Appl. No.:

8/188579

Inventors:

Charles K. Hiebert - Mountain View CA
Alan Laibelman - Menlo Park CA
Kenneth J. Ryan - Sunnyvale CA

Assignee:

SRI International - Menlo Park CA

International Classification:

A61K 3805
A61K 3806
A61K 31535
C07D26524

US Classification:

514 18

Abstract:

Novel therapeutic agents useful as inhibitors of HLE are provided. The compounds have the structural formula (I) ##STR1## wherein R. sup. 1 through R. sup. 9, m, n and p are as defined herein. Methods of using the compounds of formula (I) to inhibit serine proteases and to treat physiological conditions and disease states associated with elevated HLE levels are also provided, as are pharmaceutical compositions containing the compounds.